Koumaki Dimitra, Boumpoucheropoulos Sotirios, Koumaki Vasiliki, Katoulis Alexander, Pappas Georgia, Mantaka Aikaterini, Krasagakis Konstantinos
Dermatology Department, University Hospital of Heraklion, PAGNI, Heraklion, Crete, Greece.
Medical Oncology Department, Agii Anargiri General Oncological Hospital of Kifisia, Athens, Greece.
Eur J Case Rep Intern Med. 2020 Jan 15;7(2):001411. doi: 10.12890/2020_001411. eCollection 2020.
Agents targeting the epidermal growth factor receptor (EGFR)-mediated signalling pathway are increasingly being used for the treatment of advanced lung, pancreatic, colorectal and head and neck cancers.
Here, we report the first case of eruptive seborrhoeic keratosis following panitumumab treatment, an anti-EGFR monoclonal antibody, in a 73-year-old patient with stage 4 (IV) colorectal cancer with hepatic metastasis.
While panitumumab is an emerging therapy for RAS wild-type metastatic colorectal cancer, physicians should consider panitumumab as a potential cause of eruptive seborrhoeic keratosis.
Panitumumab is a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), indicated for the treatment of wild-type RAS metastatic colorectal cancer.Dermatologic toxicity of all grades occurs in more than 90% of patients treated with EGFR inhibitors.To the best of our knowledge, we have reported here a rare side effect; panitumumab-induced eruptive seborrhoeic keratosis.
靶向表皮生长因子受体（EGFR）介导信号通路的药物越来越多地用于治疗晚期肺癌、胰腺癌、结直肠癌和头颈癌。
在此，我们报告首例帕尼单抗治疗后发生的发疹性脂溢性角化病，该患者为一名73岁的IV期结直肠癌伴肝转移患者，使用的药物为抗EGFR单克隆抗体帕尼单抗。
虽然帕尼单抗是RAS野生型转移性结直肠癌的一种新兴治疗方法，但医生应考虑帕尼单抗是发疹性脂溢性角化病的一个潜在病因。
帕尼单抗是一种靶向表皮生长因子受体（EGFR）的全人源单克隆抗体，用于治疗野生型RAS转移性结直肠癌。超过90%接受EGFR抑制剂治疗的患者会出现各级皮肤毒性。据我们所知，我们在此报告了一种罕见的副作用；帕尼单抗诱导的发疹性脂溢性角化病。
